TIGIT Antibody [7E5] | RF16051

TIGIT Antibody [7E5] | RF16051 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: TIGIT antibody was raised against the extracellular domain of human TIGIT.

Research Area: Immunology

Tested Application: E, IHC-P, ICC, IF, Flow

Application: TIGIT antibody can be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 26 kDa

Validation: N/A

Isoform: N/A

Purification: TIGIT Antibody is supplied as protein A purified IgG2b.

Clonality: Monoclonal

Clone: [7E5]

Isotype: IgG2b

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TIGIT Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.

Concentration: 1 mg/mL

Storage Condition: TIGIT antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: TIGIT Antibody: T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3, WUCAM

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH) . TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1) . Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2) .